source
- Genentech signs $1.5 billion bispecific antibody deal with Earendil LabsGenentech, Roche's US subsidiary, announced a licensing agreement with Earendil Labs to discover and develop multiple bispecific antibodies aimed at oncology. The agreement provides a $55 million…
- FDA approves Mirum's Atebrioz for ultra-rare disease that hardens muscle and connective tissueThe U.S. Food and Drug Administration has granted approval for Mirum Pharmaceuticals' new therapy for an ultra-rare genetic disorder that causes muscle and connective tissue to turn into bone. The…